Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Share-based Compensation (2019 - 2025)

Pulmonx (LUNG) has disclosed Share-based Compensation for 7 consecutive years, with $5.2 million as the latest value for Q3 2025.

  • Quarterly Share-based Compensation fell 11.53% to $5.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $22.5 million through Sep 2025, down 2.24% year-over-year, with the annual reading at $23.0 million for FY2024, 3.86% up from the prior year.
  • Share-based Compensation for Q3 2025 was $5.2 million at Pulmonx, down from $6.2 million in the prior quarter.
  • The five-year high for Share-based Compensation was $6.2 million in Q2 2025, with the low at $2.3 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $4.7 million, with a median of $5.2 million recorded in 2025.
  • The sharpest move saw Share-based Compensation surged 1354.09% in 2021, then dropped 11.53% in 2025.
  • Over 5 years, Share-based Compensation stood at $3.0 million in 2021, then skyrocketed by 41.0% to $4.2 million in 2022, then soared by 31.81% to $5.6 million in 2023, then dropped by 1.34% to $5.5 million in 2024, then dropped by 6.46% to $5.2 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $5.2 million, $6.2 million, and $5.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.